Nutrigenomics and Cancer: How Diet May Influence Genes, Metabolism and Tumor Biology

By Editorial Team

Cancer research is entering a new era where nutrition is no longer viewed simply as “fuel” or calorie intake. Scientists are increasingly studying how nutrients interact with:

  • genes,

  • metabolism,

  • inflammation,

  • immunity,

  • and the tumor microenvironment.

This emerging field is called nutrigenomics.

Nutrigenomics explores how:

food and nutrients may influence gene expression, cellular signaling, and biological pathways involved in health and disease.

In oncology, researchers are now investigating whether nutrition could potentially affect:

  • cancer risk,

  • tumor progression,

  • treatment tolerance,

  • immune function,

  • and even responses to therapy.

What Is Nutrigenomics?

Nutrigenomics studies the interaction between:

  • nutrients,

  • genes,

  • and biological systems.

Unlike traditional nutrition science, nutrigenomics asks deeper questions such as:

  • How do nutrients influence gene expression?

  • Can diet activate or suppress cancer-related pathways?

  • Why do people respond differently to the same foods?

  • How do genetics affect metabolism and inflammation?

The field overlaps with:

  • precision medicine

  • systems biology

  • metabolomics

  • epigenetics

  • microbiome science

Genes Are Not Destiny

One of the central ideas in nutrigenomics is:

genes may influence risk, but environment often influences expression.

This is especially important in cancer.

A person may inherit genetic vulnerabilities, but:

  • inflammation,

  • metabolic dysfunction,

  • toxin exposure,

  • obesity,

  • and dietary patterns

may influence whether certain cancer-promoting pathways become activated.

Epigenetics: The Missing Link

A major focus of nutrigenomics is epigenetics.

Epigenetics refers to changes in gene activity without altering the DNA sequence itself.

Common epigenetic mechanisms include:

  • DNA methylation

  • histone modification

  • microRNA regulation

Some nutrients may influence these processes.

Diet and Gene Expression

Nutrients > Epigenetic Signaling > Gene Expression Changes

Researchers are investigating whether certain dietary compounds may affect:

  • inflammation pathways

  • oxidative stress

  • detoxification systems

  • insulin signaling

  • immune responses

  • mitochondrial function

This does not mean food can “switch off cancer” directly, but it highlights how nutrition may interact with complex biological systems.

Chronic Inflammation and Cancer

Persistent inflammation is increasingly recognized as a major driver of cancer progression.

Inflammation may promote:

  • DNA damage

  • angiogenesis

  • immune suppression

  • tumor growth

  • metastasis

Many nutrigenomics studies focus on dietary patterns that may influence inflammatory signaling.

Insulin, Glucose and Cancer Signaling

Metabolic dysfunction is another major area of interest.

High insulin and glucose levels may activate pathways linked to cancer growth, including:

  • PI3K/AKT/mTOR

  • IGF-1 signaling

High Insulin/Glucose > mTOR and IGF-1 Activation > Cell Growth Signaling

Researchers are exploring whether improving metabolic health may influence:

  • cancer risk,

  • inflammation,

  • and immune function.

This is particularly relevant for:

  • obesity-associated cancers,

  • liver cancer,

  • colorectal cancer,

  • breast cancer,

  • and pancreatic cancer.

The Mediterranean Diet and Cancer Research

One of the most studied dietary patterns in cancer prevention research is the Mediterranean diet.

It typically emphasizes:

  • olive oil

  • vegetables

  • legumes

  • fish

  • nuts

  • fiber-rich foods

  • reduced ultra-processed foods

Some studies associate this pattern with:

  • lower inflammation

  • improved metabolic health

  • reduced oxidative stress

However:

nutrition research is complex and rarely proves direct causation.

The Gut Microbiome Connection

The gut microbiome has become central to nutrigenomics.

Gut bacteria help metabolize:

  • fiber,

  • polyphenols,

  • bile acids,

  • and dietary compounds.

These microbial metabolites may influence:

  • immunity

  • inflammation

  • hormone metabolism

  • cancer signaling

Researchers are now studying whether microbiome composition may affect:

  • immunotherapy response

  • chemotherapy toxicity

  • colorectal cancer risk

  • liver cancer progression

Fiber, Short-Chain Fatty Acids and Immunity

Dietary fiber is increasingly studied because gut bacteria convert fiber into:

  • short-chain fatty acids (SCFAs)

These molecules may influence:

  • inflammation

  • T-cell function

  • intestinal integrity

  • immune signaling

Dietary Fiber > Gut Microbial Fermentation > Short-Chain Fatty Acids

Some researchers believe this gut-immune-metabolic interaction may partly influence cancer risk and treatment response.

Nutrients Being Studied in Nutrigenomics

Researchers are investigating many dietary compounds, including:

  • omega-3 fatty acids

  • curcumin

  • sulforaphane

  • polyphenols

  • vitamin D

  • green tea catechins

  • quercetin

  • resveratrol

These compounds are being studied for possible effects on:

  • inflammation

  • oxidative stress

  • immune regulation

  • mitochondrial function

  • epigenetic signaling

Importantly:

most evidence remains preliminary or observational.

Ketogenic Diets and Metabolic Oncology

Some researchers are exploring ketogenic diets in cancer care because ketosis may:

  • lower insulin levels

  • alter glucose availability

  • influence inflammation

  • affect mitochondrial metabolism

However:

  • evidence remains mixed,

  • human trials are limited,

  • and ketogenic approaches are not appropriate for every patient.

Cancer nutrition should always be individualized.

Nutrigenomics and Liver Cancer

Nutrigenomics may become especially important in liver cancer because the liver regulates:

  • glucose metabolism

  • fat metabolism

  • detoxification

  • hormone signaling

  • inflammatory pathways

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now a major driver of liver cancer worldwide.

Researchers are studying whether:

  • diet quality,

  • insulin sensitivity,

  • microbiome health,

  • and weight management

may influence liver cancer risk and progression.

Precision Nutrition and Personalized Oncology

The future of cancer care may involve:

  • genomic profiling

  • metabolic biomarkers

  • microbiome analysis

  • AI-driven nutrition modeling

  • personalized dietary strategies

This concept is sometimes called:

precision nutrition.

Rather than giving identical dietary advice to everyone, clinicians may eventually tailor nutrition based on:

  • genetics

  • metabolism

  • tumor biology

  • microbiome composition

  • treatment type

The Limits of Nutrigenomics

Nutrigenomics is promising, but important limitations remain.

Challenges include:

  • inconsistent nutrition studies

  • individual variability

  • difficulty controlling diet long-term

  • conflicting observational data

  • complex gene-environment interactions

There is currently:

no universally proven “anti-cancer diet.”

Patients should be cautious of exaggerated claims online.

What Nutrigenomics Does NOT Mean

Nutrigenomics does not mean:

  • food alone cures cancer,

  • supplements replace treatment,

  • or genetics can perfectly predict outcomes.

Cancer is extraordinarily complex.

Nutrition is best viewed as:

  • one component of a broader systems-based approach to health.

Key Takeaways

  • Nutrigenomics studies how nutrients interact with genes and biological pathways.

  • Diet may influence inflammation, metabolism, immunity, and epigenetic signaling.

  • Insulin resistance and metabolic dysfunction are increasingly linked to cancer risk.

  • The microbiome may help connect nutrition, immunity, and tumor biology.

  • Precision nutrition may become part of future personalized oncology strategies.

  • Nutrigenomics remains an evolving science with many unanswered questions.

Final Thoughts

The emerging field of nutrigenomics reflects a broader shift in medicine:

from viewing disease as isolated organ dysfunction toward understanding interconnected biological systems.

Cancer increasingly appears influenced not only by mutations, but also by:

  • metabolism,

  • inflammation,

  • immune function,

  • microbiome interactions,

  • and environmental exposures.

In the future, oncology may increasingly integrate:

  • genomics,

  • immunotherapy,

  • metabolic medicine,

  • microbiome science,

  • and personalized nutrition

into a more comprehensive systems-oncology framework.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...
Read more